Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Novo Nordisk

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Novo Nordisk To Enter Phase 3 Development in Alzheimer’s Disease with Oral Semaglutide

Contact the Supplier

Lead Product(s): Semaglutide

Therapeutic Area: Neurology Product Name: Rybelsus

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 16, 2020

Details:

Novo Nordisk announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide.

Orphazyme

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson’s Disease Research

Contact the Supplier

Lead Product(s): Arimoclomol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Michael J. Fox Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 17, 2020

Details:

Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).